First Human Trial of a New GLP-1/FGF21 Dual Agonist Shows Blood Sugar and Lipid Benefits
HEC88473, a novel drug combining GLP-1 and FGF21 receptor activity, lowered blood sugar, reduced triglycerides by up to 43%, and raised adiponectin by up to 91% in its first human trial.
Quick Facts
What This Study Found
HEC88473 is an Fc fusion protein that combines GLP-1 and FGF21 activity in a single molecule. In this phase 1 single-ascending dose trial:
- Pharmacokinetics: The drug splits into two active components after dosing — Fc-GLP-1 (half-life 66.5-119.5 hours) and Fc-FGF21 (half-life 28.4-41.6 hours), with peak levels at 12-14 hours
- Blood sugar: At doses ≥5.1 mg, glucose decreased during oral glucose tolerance tests on days 3 and 7. Maximum reduction was -1.829 mmol/L (placebo-adjusted) at 47.6 mg
- Adiponectin: At doses ≥10.2 mg, levels increased dose-dependently, up to 90.71% from baseline at 62.9 mg
- Triglycerides: At doses ≥17.0 mg, significant dose-dependent reductions up to -43.01% from baseline at 62.9 mg
- Safety: Well tolerated; most adverse events were mild GI disorders
Key Numbers
How They Did This
This was a phase 1, single-ascending dose trial (NCT05943886) in healthy and obese Chinese subjects. Participants received single subcutaneous doses of HEC88473 ranging from 0.5 to 62.9 mg or placebo. Researchers measured serum drug concentrations over time (pharmacokinetics), and tracked blood glucose (via oral glucose tolerance test), lipid levels, and adiponectin (pharmacodynamics). Safety was monitored throughout.
Why This Research Matters
The metabolic drug race is moving beyond single-target approaches. While GLP-1 drugs are effective for blood sugar and weight, adding FGF21 activity could independently improve lipid metabolism and liver health. HEC88473 represents a new strategy: combining an incretin with a metabolic growth factor. The triglyceride and adiponectin effects from a single dose are particularly notable and could be especially relevant for patients with metabolic syndrome or fatty liver disease.
The Bigger Picture
The next frontier in metabolic drug development goes beyond dual GLP-1/GIP agonists like tirzepatide. HEC88473 pairs GLP-1 with FGF21 — a pathway known for its effects on liver fat, lipid metabolism, and insulin sensitivity. Several companies are exploring FGF21-based therapies for MASH (metabolic-associated steatohepatitis), and combining it with GLP-1 could address both weight and liver disease simultaneously.
What This Study Doesn't Tell Us
This was a single-dose phase 1 study focused on safety and pharmacokinetics, not efficacy. The sample size was not disclosed in the abstract. Only Chinese subjects were enrolled, so results may not generalize to other populations. No weight loss data was reported (single-dose studies are too short to measure weight effects). The long-term safety and efficacy of repeated dosing remain unknown.
Questions This Raises
- ?Will the impressive single-dose lipid and adiponectin effects translate to meaningful clinical outcomes with repeated dosing?
- ?Could HEC88473's FGF21 component provide liver fat reduction benefits relevant to MASH treatment?
- ?How will this GLP-1/FGF21 approach compare to GLP-1/GIP (tirzepatide) or GLP-1/GIP/glucagon (retatrutide) multi-agonists for weight and metabolic outcomes?
Trust & Context
- Key Stat:
- -43% triglycerides Maximum triglyceride reduction from a single dose of HEC88473 at 62.9 mg in healthy/obese subjects
- Evidence Grade:
- This is a phase 1 single-ascending dose trial — the earliest stage of human testing. While it establishes safety and provides preliminary pharmacodynamic signals, it cannot determine clinical efficacy. Much larger and longer trials are needed.
- Study Age:
- Published in 2025, this represents cutting-edge metabolic drug development. HEC88473 is in the early stages of clinical evaluation, with further trials expected.
- Original Title:
- First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects.
- Published In:
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 39(3), 477-486 (2025)
- Authors:
- Zhang, Hong(4), Li, Qianqian(3), Chen, Hong(5), Guo, Lingfeng, Li, Jing, Xie, Can, Yan, Jiangyu, Ding, Yanhua
- Database ID:
- RPEP-14492
Evidence Hierarchy
Frequently Asked Questions
What makes HEC88473 different from existing GLP-1 drugs?
Unlike semaglutide or tirzepatide, HEC88473 combines GLP-1 activity with FGF21 — a metabolic growth factor that independently improves lipid metabolism, liver fat, and insulin sensitivity. This dual approach could offer metabolic benefits beyond what GLP-1 alone achieves.
How long would one injection of HEC88473 last?
The drug splits into two active components after injection. The GLP-1 portion has a half-life of 66-120 hours (about 3-5 days), and the FGF21 portion has a half-life of 28-42 hours (about 1-2 days), suggesting weekly or less frequent dosing may be possible.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14492APA
Zhang, Hong; Li, Qianqian; Chen, Hong; Guo, Lingfeng; Li, Jing; Xie, Can; Yan, Jiangyu; Ding, Yanhua. (2025). First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects.. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 39(3), 477-486. https://doi.org/10.1007/s40259-025-00715-3
MLA
Zhang, Hong, et al. "First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects.." BioDrugs : clinical immunotherapeutics, 2025. https://doi.org/10.1007/s40259-025-00715-3
RethinkPeptides
RethinkPeptides Research Database. "First-in-Human Study on Tolerability, Pharmacokinetics, and ..." RPEP-14492. Retrieved from https://rethinkpeptides.com/research/zhang-2025-firstinhuman-study-on-tolerability
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.